

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the prospectus dated 15 December 2022 (the “Prospectus”) of Guanze Medical Information Industry (Holding) Co., Ltd. (the “Company”).

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilising) Rules (Chapter 571W of the Laws of Hong Kong).

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities in Hong Kong, the United States or elsewhere. This announcement is not a prospectus.

This announcement is not for release, publication or distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia) or any other jurisdiction where such distribution is prohibited by law. This announcement does not constitute or form a part of any offer to sell or a solicitation of an offer to buy securities in the United States or in any other jurisdiction. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any applicable state securities laws, and may not be offered, sold, pledged or transferred in the United States unless pursuant to an exemption from, or in a transaction that is not subject to, the registration requirements of the U.S. Securities Act and any applicable state securities laws. The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act. There will be no public offering of the securities of the Company in the United States.

Guanze Medical Information Industry (Holding) Co., Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2427)

END OF STABILISATION PERIOD, NO STABILISING ACTION AND LAPSE OF THE OVER-ALLOTMENT OPTION

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong).

END OF STABILISATION PERIOD

The Company announces that the stabilisation period in connection with the Global Offering ended on Thursday, 19 January 2023, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering.

NO STABILISING ACTION AND LAPSE OF OVER-ALLOTMENT OPTION

The Overall Coordinator and the Joint Global Coordinators have confirmed to the Company that there was no over-allocation in the International Offering. Therefore, the Overall Coordinator and the Joint Global Coordinators (for themselves and on behalf of the International Underwriters and the Capital Market Intermediaries) did not exercise the Over-allotment Option, and no stabilising action in relation to the Global Offering was taken by the Stabilising Manager, its affiliates or any person acting for it during the stabilisation

period. The Over-allotment Option was not exercised at all and lapsed on Thursday, 19 January 2023, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. Accordingly, no Share was or will be issued under the Over-allotment Option.

PUBLIC FLOAT

The Company continues to comply with the public float requirement under Rule 8.08(1)(a) of the Listing Rules whereby at least 25% of the Company's total number of issued Shares must at all times be held by the public.

By order of the Board
Guanze Medical Information Industry (Holding) Co., Ltd.
Meng Xianzhen
Chairman of the Board

Hong Kong, 19 January 2023

As at the date of this announcement, the executive Directors are Mr. Meng Xianzhen and Mr. Guo Zhenyu, the non-executive Director is Ms. Meng Cathy, the independent non-executive Directors are Dr. Zhao Bin, Dr. Chang Shiwang and Dr. Wong Man Hin Raymond.